Price
Target price
-
-
-
-
-
?14.71
WKN: A1W77U / Symbol: KPTI / Name: Karyopharm / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Karyopharm Therapeutics Inc. Stock
Karyopharm Therapeutics Inc. is currently one of the favorites of our community with 14 Buy predictions and no Sell predictions.
With a target price of 14 € there is potential for a 2486.84% increase which would mean more than doubling the current price of 0.54 € for Karyopharm Therapeutics Inc..
Our community identified positive and negative aspects for Karyopharm Therapeutics Inc. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Karyopharm Therapeutics Inc. stock. On the other hand our users think that "Unique positioning" could be a problem in the future.
Pros and Cons of Karyopharm Therapeutics Inc. in the next few years
Pros
?
S********** s********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Karyopharm Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Karyopharm Therapeutics Inc. | - | - | - | - | - | - | - |
| Ardelyx Inc. | 5.570% | 2.840% | 1.187% | 5.509% | 6.465% | 176.349% | -3.856% |
| Krystal Biotech | 0.330% | 3.678% | 18.962% | 25.776% | 37.057% | 193.803% | - |
| Evolus Inc | -4.200% | -1.724% | -8.065% | -47.706% | -45.714% | -18.571% | 88.742% |
Comments
Karyopharm Therapeutics (NASDAQ:KPTI) had its price target lowered by analysts at Royal Bank Of Canada from $30.00 to $19.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics (NASDAQ:KPTI) was upgraded by analysts at HC Wainwright from a "neutral" rating to a "buy" rating. They now have a $15.00 price target on the stock.
Show more
Ratings data for KPTI provided by MarketBeat
Karyopharm Therapeutics (NASDAQ:KPTI) had its "overweight" rating reaffirmed by analysts at Piper Sandler. They now have a $12.00 price target on the stock, down previously from $15.00.
Show more
Ratings data for KPTI provided by MarketBeat
